Compare · IVF vs MDLN
IVF vs MDLN
Side-by-side comparison of INVO Fertility Inc. (IVF) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IVF and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.21B, about 17623.4x IVF ($2.7M).
- Over the past year, IVF is down 99.0% and MDLN is down 11.9% - MDLN leads by 87.1 points.
- MDLN has been more active in the news (26 items in the past 4 weeks vs 8 for IVF).
- MDLN has more recent analyst coverage (25 ratings vs 0 for IVF).
PerformanceIVF-71.31%MDLN-11.88%
2025-12-17+0.00%2026-06-18
- Company
- INVO Fertility Inc.
- Medline Inc.
- Price
- $1.53-2.85%
- $35.91-1.41%
- Market cap
- $2.7M
- $47.21B
- 1M return
- +7.72%
- -4.76%
- 1Y return
- -98.95%
- -11.88%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 26
- Recent ratings
- 0
- 25
Latest IVF
- INVO Fertility Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form PRE 14A filed by INVO Fertility Inc.
- Amendment: SEC Form 10-K/A filed by INVO Fertility Inc.
- INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
- INVO Fertility Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by INVO Fertility Inc.
- INVO Fertility Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits
- INVO Fertility Announces Fiscal Year 2025 Financial Results
- SEC Form NT 10-Q filed by INVO Fertility Inc.
- INVO Fertility Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)